Safety Study of PP-007 in Subjects With Acute Ischemic Stroke

Completed · Phase 1

Conditions studied: Acute Ischemic Stroke

In brief

The HEMERA-1 Extension (Part III) is a prospective, open-label, multicenter study to evaluate safety of two doses of PP-007 in Acute Ischemic Stroke (AIS) subjects receiving Intravenous Thrombolysis (IVT) or mechanical thrombectomy (MT) or IVT+MT as standard of care (SOC). Subjects will receive two doses of PP-007 infusion 24 ± 6 hours apart in addition to the site-specific SOC protocol. PP-007 is PEGylated bovine carboxyhemoglobin and will be administered via IV infusion. The effects on collateral flow, infarct size and functional outcomes will be evaluated.

Key facts

Study ID

NCT04677777

Run by

Prolong Pharmaceuticals

People needed

24

Starts

2024-04-24

Expected to finish

2025-02-20

Last updated by the study team

2025-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject or subject's LAR has provided informed consent.
• ≥18 years of age.
• If the patient were to receive MT, patient must have a history of last seen well ≤ 24 hours prior to start of MT
• If the patient were to receive IVT, patient must have a history of last seen well ≤ 4.5 hours prior to start of IVT or as per Institution SOC Note: Onset is defined as the time point when symptoms first began, or if unknown, the last time point when the subject reported or was observed having normal (baseline) neurological function.
• AIS patient with ASPECTS ≥ 3 to 10
• AIS patient with life expectancy of 90 days, as determined by the investigator
• Patient with disabling stroke defined as baseline NIHSS ≥ 6 prior to IP administration
• mRS ≤ 2 (pre-morbid), prior to onset of symptoms (self-reported or family/caregiver reported)
• At the time of stroke, patient must be living in their own home, apartment or seniors lodge where no nursing care/support is required
• Subject and caregiver are available for protocol-required follow-up visits
• Contraception and pregnancy:
• Male subjects, and females of childbearing potential (subjects and female partners of male subjects who are ovulating, premenopausal, and not surgically sterile) must use a highly effective method of contraception consistently and correctly during study participation and up to 90 days following PP-007 infusion.
• Highly effective methods of contraception are those that, either alone or in combination, result in a failure rate of <1% per year when used consistently and correctly, including:
• i. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (i.e., oral, intravaginal, or transdermal).
• ii. Progesterone-only hormonal contraception associated with inhibition of ovulation (i.e., oral, injectable, or implantable).
• iii. Intrauterine device, intrauterine hormone-releasing system, or bilateral tubal occlusion.
• iv. Male sterilization performed more than six months prior to Screening. v. Sexual abstinence. c. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before Screening) or postmenopausal, defined as spontaneous amenorrhea for at least 12 months.
• d. Male subjects must abstain from sperm donation during study participation and up to 90 days following PP-007 infusion.
• e. Female subjects of childbearing potential must have negative results for the pregnancy test at Screening/Baseline.

You may not qualify if…

• <!-- -->
• ASPECTS < 3 on NCCT
• Multi-arterial territorial strokes (e.g. bilateral, anterior and posterior circulation)
• Evidence of symptomatic intracranial hemorrhage, including subarachnoid hemorrhage, on initial CTA/CTP, or history of intracranial hemorrhage within the last 30 days.
• Pre-existing neurological or psychiatric disease that would confound neurological or functional evaluations in the opinion of the Investigator.
• A seizure at stroke onset that precludes obtaining an accurate screening NIHSS and mRS assessment
• Clinical history, past imaging, or clinical judgment suggests that the intracranial occlusion is chronic
• History of severe head injury within 90 days of Baseline with residual neurological deficit at the time of AIS.
• Clinically significant heart disease including:
• a. Symptoms or ECG evidence of acute myocardial infarction or unstable angina. b. Cardiac arrhythmia associated with hemodynamic instability. c. Heart failure (New York Heart Association Class III or IV) or known ejection fraction <30%.
• d. ECG with second- or third-degree heart block in the absence of a permanent pacemaker.
• Refractory BP (systolic >200 and/or diastolic >120 mmHg).
• Confirmed diagnosis of septic embolus or bacterial endocarditis within the past six months.
• Aortic dissection.
• Contraindication to radiographic imaging procedures including:
• a. Known hypersensitivity to radiographic contrast agents. b. Known renal insufficiency precluding repeated contrast administration.
• Prior treatment (within the last 30 days) or planned concurrent treatment with an investigational medication or device.
• Blood glucose <50 mg/dL (2.78 mmol) or >400 mg/dL (22.20 mmol) that is not responsive to appropriate treatment at Baseline.
• Known bleeding disorder (e.g., coagulopathy or thrombocytopenia).
• a. Platelet count <50,000/μL at Baseline b. Any anticoagulants within the previous 48 hours that leads to Prothrombin Time (International Normalization Ratio [INR]) ≥2.0 and/or activated partial thromboplastin time (aPTT) ≥40 sec at baseline.
• c. Any dual antiplatelet agents (e.g., aspirin plus clopidogrel) within the previous 48 hours that leads to Prothrombin Time (INR ≥ 2.0 and or aPTT ≥ 40 sec at baseline)
• Known history or current evidence of renal or hepatic disease including:
• Documented renal insufficiency (serum creatinine >3.0 × ULN).
• History of liver disease (i.e., alanine transaminase [ALT] and/or Aspartate transaminase (AST) >2 × ULN and/or conjugated bilirubin >1.5 mg/dL).
• Note: A subject without history or current evidence of renal or hepatic disease does not require creatinine, ALT, AST, or bilirubin results to be available prior to enrollment.

Where it is running

• Baptist Health Research Institute — Jacksonville, Florida, United States
• Baptist Health Miami Cardiac & Vascular Institute (MCVI) — Miami, Florida, United States
• Emory University School of Medicine — Atlanta, Georgia, United States
• Saint Luke's Hospital — Kansas City, Missouri, United States
• Mercy Health - St. Vincent Medical Center — Toledo, Ohio, United States
• University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States
• Oregon Stroke Center at Oregon Health & Science University (OHSU) — Portland, Oregon, United States
• UPMC Stroke Institute — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.